Follow on Google News News By Tag * Osteoporosis * Treatment * Clinical * Pipeline * Trial * Anabolic * Therapies * Bone * Focusing * Preclinical * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Recent Study: R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatmentFast Market Research recommends "R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment" from Datamonitor, now available
Over the last 12 months, there have been encouraging developments in the osteoporosis pipeline, with new therapies either receiving regulatory approval or launching. Moreover, both in the clinical and preclinical pipeline, companies continue their quest to bring to market a new, safe, effective, and affordable anabolic drug to address unmet need in the osteoporosis market. Features and benefits * Understand key dynamics in the R&D pipeline for new osteoporosis therapies * Benchmark novel and existing therapies using the target product profile identified by Datamonitor * Support R&D decision making by evaluating osteoporosis clinical trial designs that have set a precedent, as well as analysis of discontinued projects * Access Datamonitor's prediction of how the treatment landscape may change in the next 20 years Highlights ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ The osteoporosis pipeline remains well stocked, with several products continuing their clinical trials and no significant discontinuations. There most exciting novel candidates with new mechanisms of action continue to be the new antiresorptives cathepsin K inhibitors and the anti-sclerostin monoclonal antibodies anabolics. The osteoporosis treatment paradigm has been largely static for the past 20 years, but this trend is likely to change as new drugs reach the market. It is probable that the fracture prevention strategy will evolve from just focusing on increasing bone mineral density to improving the bone quality and strength. The major change in the treatment of osteoporosis will be the launch of new efficacious and safe anabolic treatments, allowing physicians to use these treatments earlier in the algorithm and in a wider category of patients. In particular companies are targeting the Wnt pathway, bone morphogenetic proteins, and insulin-like growth factor. Your key questions answered * What are the key trends in the osteoporosis pipeline? * What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market? * How will new osteoporosis treatments evolve in the next 20 years? * What are the requirements of eopean and US regulatory bodies to ensure approval of a novel candidate? Report Table of Contents: Executive Summary Strategic scoping and focus Datamonitor key findings Related reports OVERVIEW Catalyst Summary CLINICAL PIPELINE OVERVIEW Osteoporosis pipeline The osteoporosis pipeline remains robust Companies are focusing on developing anabolics as competition in the antiresorptive market increases Mechanism of action Late-stage development compounds recently discontinued TARGET PRODUCT PROFILE Comparator therapies Fosamax (alendronate; Target product profile versus current level of attainment CLINICAL TRIAL DESIGN IN OSTEOPOROSIS Preclinical trials Two different animal species tests are required by both the FDA and EMA Preclinical trial design should reflect the clinical indication Clinical trials The FDA and EMA have different patient inclusion requirements for osteoporosis trials Clinical endpoints Future developments in clinical trial design Trial endpoints unlikely to change INNOVATIVE EARLY-STAGE APPROACHES New targets for osteoporosis treatments Targets for antiresorptive treatment Targets for anabolic treatment THE FUTURE OF TREATMENT OF OSTEOPOROSIS Screening and osteoporosis diagnosis Increased use of FRAX will lead to more osteoporosis prevention Change in treatment outcomes Focusing on bone quality New treatment strategies Anabolic treatments are likely to be used earlier in the treatment algorithm Combination therapies Personalized medicine BIBLIOGRAPHY Journal papers Websites APPENDIX Contributing experts Conferences attended Report methodology About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|